FEB 02, 2016 09:00 AM PST

Arrays or RNA-Seq? Choosing the right tool for the job

Sponsored by: Affymetrix, Affymetrix
  • Research Associate Professor, Biomedical Sciences, Director, Microarray and NextGen Sequencing Core, Center for Functional Genomics, SUNY Albany
      Dr. Sridar Chittur received a Bachelor's degree in Pharmacy from Bombay University (India), a Ph.D. in Medicinal Chemistry from West Virginia University and an M.B.A in New Venture Development from the University at Albany. He did his post-doctoral training in Enzymology/Pharmacology at the Purdue University School of Pharmacy, following which he briefly worked at Myomatrix Therapeutics LLC. He is currently a Research Associate Professor in the Department of Biomedical Sciences at the University at Albany's School of Public Health. He also directs the Microarray and High Throughput DNA Sequencing Core at the Center for Functional Genomics. His research interests include epigenetics, high throughput screening technologies and drug discovery. He is also an active member of the Association of Biomolecular Facilities (ABRF) and serves on various ABRF Research Groups that focus on studies of nucleic acids, genomics and flow cytometry.
    • Assistant Research Professor, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine
        Dr. Yesim Gökmen-Polar is an Assistant Research Professor in the Department of Pathology and Laboratory Medicine at Indiana University School of Medicine. Her research interests are centered on the identification of novel therapeutic targets in breast and thymic cancers resistant to standard of care therapy. She has approximately 50 publications mainly in the field of cancer biology. Her specific expertise is in development of novel therapeutic targets (i.e. targeting EphA2 receptor tyrosine kinase, protein kinase C beta, anti-tubulins and TORC1/2) in colon, breast cancer and thymic malignancies. Her lab developed and characterized a novel human thymoma model, designated as IU-TAB-1, which was derived from a patient with the stage II thymoma (WHO type A/B). Dr. Gökmen-Polar's current research uses next generation sequencing (NGS), next generation microarrays such as Clariom D Human Transcriptome Analysis, and preclinical models to understand the transcriptional regulation/mechanisms of resistance and develop novel targeted therapies. The ultimate goal of her research is to prevent development of recurrences and improve the quality of life for patients.

      DATE: February 2nd, 2016
      TIME:  9am pacific time, 12pm eastern time

      What is the most appropriate technology to empower your research?
      Next generation sequencing (NGS) for RNA (RNA-Seq) has advanced significantly over the last decade having gained popularity for investigating a wide variety of complex diseases at the transcriptome level. While RNA-Seq is an appropriate technology for de novo discovery, it has significant limitations particularly for detecting low abundance transcripts and alternative splicing events, both of which require very deep sequencing. Increasing sequencing depth can result in dramatically increased costs and the requirement for considerable expertise in bioinformatics to effectively analyze data. The scientific community now widely acknowledges that there are specific applications best served by arrays and others by RNA-Seq. Additionally, many see an opportunity to harness the power of both technologies for expression studies.
      During this webinar, the speakers will:
      • Discuss the pros and cons of each technology along with platform application suitability
      • Demonstrate how arrays and RNA-Seq can be used to complement each other
      • Explain how recently developed next generation arrays from Affymetrix can be used to overcome the limitations of RNA-Seq in both research and clinical settings
      • Answer your questions live during the broadcast!

      Show Resources
      Show Resources
      Connect with us